📣 VC round data is live. Check it out!
Translational Development Valuation Multiples
Discover Translational Development's revenue and EBITDA valuation multiples and M&A history.
Translational Development Overview
About Translational Development
Translational Development Acquisition Corp is a newly organized blank check company.
Founded
2022
HQ
Employees
2
Financials (FY)
EV
$236M
Valuation Multiples
Start free trial
Translational Development Financials
Translational Development reported last fiscal year revenue of - and negative EBITDA of ($945K).
In the same fiscal year, Translational Development generated ($945K) in EBITDA losses and $6M in net income.
Translational Development P&L
In the most recent fiscal year, Translational Development reported revenue of - and EBITDA of ($945K).
Translational Development is profitable as of last fiscal year, with EBITDA margin of - and net margin of -.
Financial data powered by Morningstar, Inc.
Translational Development Stock Performance
Translational Development has current market cap of $236M, and enterprise value of $236M.
Translational Development's stock price is $10.75.
Translational Development has an EPS (earnings per share) of $0.29.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $236M | $236M | 0.1% | - | - | - | $0.29 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTranslational Development Valuation Multiples
Translational Development trades at (249.8x) EV/EBITDA.
Translational Development Financial Valuation Multiples
As of June 5, 2026, Translational Development has market cap of $236M and EV of $236M.
Translational Development has a P/E ratio of 37.0x.
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Translational Development Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Translational Development Margins & Growth Rates
Translational Development Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Translational Development Operational KPIs
Translational Development's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.5M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
Translational Development Competitors
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
This data is available for Pro users. Sign up to see all Translational Development competitors and their valuation data. Start Free Trial | ||||||
Acquisitions by Translational Development
Translational Development has acquired 1 company to date.
Last acquisition by Translational Development was on May 26th 2026. Translational Development acquired ProLogium Technology for $4B (EV/Revenue multiple available to Pro users).
Latest Acquisitions by Translational Development
| Description | ProLogium Technology is a Taiwan-based producer of solid-state lithium batteries featuring ultra-thin, flexible cells with energy densities exceeding 400 Wh/kg. Taoyuan-headquartered, it manufactures bipolar stacked designs for EVs, consumer electronics, and drones, achieving 20-minute fast charging. With gigafactory capacity reaching 24 GWh by 2024, ProLogium supplies BMW and Mercedes-Benz prototypes. Founded in 2006 as a National Tsing Hua University spinout, it holds over 1,000 patents. |
| HQ Country |  |
| HQ City | Taoyuan |
| Deal Date | 26 May 2026 |
| Valuation | $4B |
| EV/Revenue | |
| EV/EBITDA | |
This data is available for Pro users. Sign up to see all Translational Development acquisitions and their M&A valuation multiples. Start Free Trial | |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Translational Development
| When was Translational Development founded? | Translational Development was founded in 2022. |
| Where is Translational Development headquartered? | Translational Development is headquartered in United States. |
| How many employees does Translational Development have? | As of today, Translational Development has over 2 employees. |
| Is Translational Development publicly listed? | Yes, Translational Development is a public company listed on Nasdaq. |
| What is the stock symbol of Translational Development? | Translational Development trades under TDAC ticker. |
| When did Translational Development go public? | Translational Development went public in 2025. |
| Who are competitors of Translational Development? | Translational Development main competitors include |
| What is the current market cap of Translational Development? | Translational Development's current market cap is $236M. |
| Is Translational Development profitable? | No, Translational Development is not profitable. |
| How many companies Translational Development has acquired to date? | As of June 2026, Translational Development has acquired 1 company. |
| What was the largest acquisition by Translational Development? | $4B acquisition of ProLogium Technology on 26th May 2026 was the largest M&A Translational Development has done to date. |
| What companies Translational Development acquired? | Translational Development acquired ProLogium Technology. |
| In how many companies Translational Development has invested to date? | Translational Development hasn't invested in any companies yet (or none have been disclosed publicly). |
Lists including Translational Development
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.